791098-81-2

Usage

Uses

Used in Organic Chemistry:
Benzenemethanamine, 2,4-difluoro-.alpha.-methyl-, hydrochloride (1:1), (.alpha.R)is used as a chemical intermediate for the synthesis of various organic compounds. Its unique structure and properties make it a valuable building block in the development of new molecules with potential applications in pharmaceuticals, materials science, and other fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Benzenemethanamine, 2,4-difluoro-.alpha.-methyl-, hydrochloride (1:1), (.alpha.R)is used as a key component in the production of certain drugs. Its specific properties, such as the presence of fluorine atoms and the (.alpha.R)stereochemistry, can contribute to the drug's efficacy, stability, and bioavailability.
Used in Materials Science:

Downstream Products

• 1616340-73-8 (R)-methyl 5-((1-(2,4-difluorophenyl)ethyl)carbamoyl)-1-(2,2-dimethoxyethyl)-3-methoxy-4-oxo-1,4-dihydropyridine-2-carboxylate 
• 1616340-74-9 (R)-methyl 5-((1-(2,4-difluorophenyl)ethyl)carbamoyl)-1-(2,2-dihydroxyethyl)-3-methoxy-4-oxo-1,4-dihydropyridine-2-carboxylate 
• 1616339-78-6 (2S,5R,13aS)-N-((R)-1-(2,4-difluorophenyl)ethyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octaliydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide 

Relevant academic research and scientific papers

N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.